CenterBook Partners LP Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN

CenterBook Partners LP acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 20,350 shares of the specialty pharmaceutical company’s stock, valued at approximately $876,000.

Several other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Supernus Pharmaceuticals in the second quarter worth $434,871,000. Bank of America Corp DE increased its stake in shares of Supernus Pharmaceuticals by 37.2% in the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after buying an additional 193,479 shares in the last quarter. Ashford Capital Management Inc. increased its stake in shares of Supernus Pharmaceuticals by 5.4% in the first quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock valued at $33,360,000 after buying an additional 32,843 shares in the last quarter. Rice Hall James & Associates LLC increased its stake in shares of Supernus Pharmaceuticals by 2.0% in the first quarter. Rice Hall James & Associates LLC now owns 477,416 shares of the specialty pharmaceutical company’s stock valued at $24,678,000 after buying an additional 9,530 shares in the last quarter. Finally, Systematic Financial Management LP raised its holdings in shares of Supernus Pharmaceuticals by 23.6% in the first quarter. Systematic Financial Management LP now owns 376,079 shares of the specialty pharmaceutical company’s stock valued at $19,440,000 after buying an additional 71,853 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $28.75 on Wednesday. The stock’s fifty day moving average price is $40.39 and its two-hundred day moving average price is $46.60. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.92 and a 52-week high of $42.81. The company has a market cap of $3.39 billion, a price-to-earnings ratio of 8.03, a P/E/G ratio of 0.52 and a beta of 0.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.14). The firm had revenue of $208.60 million during the quarter, compared to analyst estimates of $217.56 million. Supernus Pharmaceuticals had a net margin of 32.75% and a negative return on equity of 418.04%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period last year, the business posted ($0.80) earnings per share. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.85 EPS for the current fiscal year.

Supernus Pharmaceuticals Announces Dividend

The company also recently declared a special dividend, which was paid on Friday, November 6th. Stockholders of record on Friday, October 30th were paid a dividend of $8.13 per share.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SUPN. Weiss Ratings downgraded shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Jefferies Financial Group started coverage on shares of Supernus Pharmaceuticals in a report on Wednesday, November 4th. They set a “strong-buy” rating on the stock. Zacks Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Bank of America began coverage on shares of Supernus Pharmaceuticals in a research note on Monday. They issued a “buy” rating and a $47.00 target price for the company. Finally, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Supernus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $60.20.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease. The company’s marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson’s disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson’s disease.